

20 March 2008

Dear Consultee/Commentator,

Single Technology Appraisal

Lapatinib for the treatment of previously treated women with advanced, metastatic or recurrent breast cancer

I am writing to update you on the status of this single technology appraisal (STA).

Unfortunately due to delays in the European regulatory timings for lapatinib, we are unable to circulate the Appraisal Consultation Document (ACD) for consultation. As a result we have also had to cancel the April consideration meeting. We understand you will find this news disappointing and will be in touch with timings as soon as we receive an update regarding licensing status.

If you have any other questions or queries please contact Eloise Saile on 020 7045 2243 or by email: eloise.saile@nice.org.uk.

Yours sincerely

Dr Carole Longson
Director, Centre for Health Technology Evaluation